🇺🇸 exenatide, long acting release in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Gastroenteritis — 2 reports (18.18%)
  2. Anaemia — 1 report (9.09%)
  3. Bladder Cancer — 1 report (9.09%)
  4. Blood Amylase Decreased — 1 report (9.09%)
  5. Blood Creatine Phosphokinase Decreased — 1 report (9.09%)
  6. Blood Creatinine Increased — 1 report (9.09%)
  7. Blood Potassium Increased — 1 report (9.09%)
  8. Blood Urea Increased — 1 report (9.09%)
  9. C-Reactive Protein Increased — 1 report (9.09%)
  10. Cellulitis — 1 report (9.09%)

Source database →

exenatide, long acting release in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Diabetes approved in United States

Frequently asked questions

Is exenatide, long acting release approved in United States?

exenatide, long acting release does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for exenatide, long acting release in United States?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.